Naprod Life Sciences Private Limited

Naprod Life Sciences Private Limited, established on July 30, 1990, is a private unlisted pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U24230MH1990PTC057496 and is registered with the Registrar of Companies, Mumbai. Initially known as Neon Antibiotics Private Limited, it rebranded to Naprod Life Sciences Private Limited in 2006.

The authorized capital of Naprod Life Sciences is ₹4.00 crore, with a paid-up capital of ₹3.02 crore. As of the latest available data, the company employs approximately 504 professionals. The registered office is located at 304 Town Centre, Andheri Kurla Road, Andheri (East), Mumbai, Maharashtra, 400059.

Naprod Life Sciences operates a state-of-the-art manufacturing plant situated in Tarapur, Thane, Maharashtra. This facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with a strong emphasis on oncology and anesthesia products. The plant adheres to current Good Manufacturing Practices (cGMP) as outlined by the World Health Organization (WHO), ensuring high-quality production standards.

The leadership team at Naprod Life Sciences includes:

• Mohan Babulal Jain – Director, appointed on March 2, 1994.

• Manish Babulal Jain – Director, appointed on September 11, 2018.

• Aarya Mohan Jain – Additional Director, appointed on March 13, 2025.

These individuals play pivotal roles in steering the company's strategic direction and operations.

Naprod Life Sciences has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, Therapeutic Goods Administration (TGA) in Australia, and Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. These approvals facilitate the company's market access and distribution in these regions.

Naprod Life Sciences has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have received prequalification from the World Health Organization (WHO), enabling access to these regions. This prequalification underscores the company's commitment to meeting international quality standards and broadens its market reach.

The company's geographic strategy demonstrates a balanced approach, with a strong presence in both regulated and emerging markets. This diversification mitigates concentration risk and positions Naprod Life Sciences to leverage growth opportunities across different regions. The strategic direction focuses on expanding market share in oncology and anesthesia segments globally.

Naprod Life Sciences has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has received approvals for its Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) for its products. The facilities have undergone FDA inspections, which have been completed satisfactorily, reflecting the company's commitment to maintaining high-quality manufacturing practices.

The manufacturing facility of Naprod Life Sciences is accredited with Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications affirm the company's adherence to international quality standards in pharmaceutical manufacturing.

In India, Naprod Life Sciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and approvals from state drug controllers. The company has obtained No Objection Certificates (NOCs) for export from the Directorate General of Foreign Trade (DGFT), facilitating its international trade operations.

As of the latest available information, there have been no reported Form 483 observations, warning letters, or import alerts issued by regulatory authorities against Naprod Life Sciences. This indicates a clean regulatory record, reflecting the company's commitment to compliance and quality standards.

In the oncology and anesthesia segments, Naprod Life Sciences faces competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly disclosed, the company's focus on high-quality, specialized formulations positions it favorably in niche markets. The company's adherence to international quality standards and its global regulatory approvals enhance its competitive edge.

Naprod Life Sciences distinguishes itself through its specialization in oncology and anesthesia products, leveraging advanced manufacturing technologies such as lyophilization. The company's commitment to innovation, high-quality production, and adherence to international regulatory standards are key competitive advantages.

Naprod Life Sciences is strategically positioned as a leading manufacturer of specialized pharmaceutical formulations, focusing on oncology and anesthesia. The company's future outlook includes expanding its product portfolio, enhancing manufacturing capabilities, and increasing market penetration in both regulated and emerging markets. The strategic direction emphasizes innovation, quality, and global market expansion.

Naprod Life Sciences has a strong track record in pharmaceutical manufacturing, with a focus on oncology and anesthesia products. The company's export volume and consistency are supported by its adherence to international quality standards and regulatory approvals. Reliability indicators include its WHO and EU GMP certifications, FDA approvals, and successful inspections by regulatory authorities.

Importers should verify the following certifications when considering Naprod Life Sciences as a supplier:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

• WHO GMP Certification: Ensure the manufacturing facility holds Good Manufacturing Practice certification from the World Health Organization.

• EU GMP Certification: Verify the facility's compliance with Good Manufacturing Practice standards as recognized by the European Union.

• ISO Certifications: Check for relevant International Organization for Standardization certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting the company directly.

When conducting due diligence on Naprod Life Sciences, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's approvals from relevant regulatory authorities in target markets.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities for compliance with international quality standards.

• Review Financial Health: Analyze the company's financial statements for profitability, liquidity, and solvency.

• Check Compliance Records: Investigate any past regulatory actions, including warning letters or import alerts.

• Evaluate Supply Chain Reliability: Assess the company's supply chain for consistency and reliability in product delivery.

Red flags to watch for include unresolved regulatory issues, financial instability, and inconsistent product quality. Recommended pre-order checks involve verifying product quality through samples, assessing lead times, and confirming after-sales support.